S&P Futures
3,830.25 -3.75 (-0.10%) Dow Futures
30,896.00 -40.00 (-0.13%) Nasdaq Futures
11,805.25 -3.25 (-0.03%) Russell 2000 Futures
1,738.40 -3.30 (-0.19%) Crude Oil
99.93 +0.43 (+0.43%) Gold
1,768.00 +4.10 (+0.23%)
Addex Therapeutics Ltd (ADXN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.1900 |
| Open | 1.2000 |
| Bid | 1.1900 x 1400 |
| Ask | 1.2700 x 900 |
| Day's Range | 1.1000 - 1.2900 |
| 52 Week Range | 1.0300 - 10.2800 |
| Volume | |
| Avg. Volume | 31,950 |
| Market Cap | 7.651M |
| Beta (5Y Monthly) | 1.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.2640 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ADXN
Related Research
- Addex Therapeutics LtdDaily – Vickers Top Buyers & Sellers for 04/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat3 months agoArgus Research
- GlobeNewswire
Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson’s Disease due to Slow Recruitment Rate
COVID-19 related challenges negatively impacted patient recruitment Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 17, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it has terminated the Phase 2b/3 study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson’s disease (PD-LID) due to the slow recrui
- GlobeNewswire
Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 27, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that the outcome of a small Phase 2a feasibility study of dipraglurant in patients with blepharospasm was inconclusive and did not meet all of its objectives. Dipraglurant is a metabotropic glutamate receptor subtype 5 negative allosteric modul
- GlobeNewswire
Addex Announces Participation in the H.C. Wainwright Global Investment Conference
Geneva, Switzerland, May 19, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will be virtually attending the H.C. Wainwright Global Investment Conference taking place May 23 - 26, 2022. Mr. Dyer has also submitted a pre-recorded video presentation to the conference, in which he provides a corporate update and discusses recent developments at
